August 25, 2011



Rigel to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at two separate investor conferences in September. Details of the events are as follows:

Stifel Nicolaus Healthcare Conference 2011 Date: Thursday, September 8th at 10:20 a.m. ET Location: Boston, MA Speaker: James M Gower

UBS Global Life Sciences Conference Date: Tuesday, September 20th at 1:30 p.m. ET Location: New York, NY Speaker: Ryan Maynard

Both presentations will be webcast. To access the live audio webcast or subsequent archived recording, log on to <u>www.rigel.com</u>. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (<u>www.rigel.com</u>)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its Phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that has completed Phase 1 trials for asthma.

Contact: Ryan Maynard Phone: 650.624.1284 Email: invrel@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.